Radiopharm Amends 20-F, Details 34 Patents & Board Attendance

TL;DR

**RDPTF's updated 20-F/A reveals a solid 34-patent portfolio and strong board engagement, signaling a stable foundation for its pipeline, making it a potential long-term hold for risk-tolerant investors.**

AI Summary

Radiopharm Theranostics Ltd (RDPTF) filed an Amendment No. 1 to its Form 20-F for the fiscal year ended June 30, 2025, primarily to update its Intellectual Property and Patent Portfolio and Board Practices sections. The company currently owns or has licensed rights under 34 granted patents, with key assets including PD-L1, HER-2, TROP-2, PTK7, V6 Integrin, Pivalate, PSA-mAb, and B7-H3. For instance, the PD-L1-a patent is granted in 2 US jurisdictions and China, with an expiry in 2036 (China) and 2037 (US, Europe). The PD-L1-b patent is granted in China, US, Japan, and Europe, with expiry dates ranging from 2037 to 2039. The HER-2 patent is granted in China, Japan, and US, expiring in 2038. The Board of Directors held 7 meetings during the fiscal year, with all directors, including CEO Riccardo Canevari and Chairman Paul Hopper, attending all eligible meetings. The Audit Committee held 3 meetings, attended by Ian Turner and Hester Larkin, while the Remuneration Committee also held 3 meetings, attended by Hester Larkin and Leila Alland. The filing also includes certifications from the CEO and CFO under Sections 302 and 906 of the Sarbanes-Oxley Act.

Why It Matters

This amendment provides crucial transparency on Radiopharm Theranostics' core intellectual property, which is vital for a biotech company's valuation and competitive moat. Investors can now see the specific granted patents, their jurisdictions, and expiry dates, offering a clearer picture of the company's long-term asset protection against competitors. The detailed board meeting attendance also sheds light on corporate governance and director engagement, which can influence investor confidence. In a highly competitive radiopharmaceutical market, robust IP and strong governance are key differentiators for RDPTF.

Risk Assessment

Risk Level: medium — The risk level is medium due to the inherent uncertainties in biotechnology patent matters, as explicitly stated in the filing: "Patent matters in biotechnology are highly uncertain and involve complex legal and factual questions." While Radiopharm Theranostics owns or has licensed 34 granted patents, the filing also notes that "the availability and breadth of claims allowed in biotechnology and pharmaceutical patents cannot be predicted," and that third parties may challenge or invalidate patents, potentially leading to costly litigation and impacting commercialization.

Analyst Insight

Investors should scrutinize the specific patent expiry dates and jurisdictions detailed in the filing to assess the longevity and global reach of Radiopharm Theranostics' intellectual property. Given the inherent risks in biotech IP, investors should also monitor future patent litigation or challenges that could impact the company's competitive position and financial performance.

Financial Highlights

debt To Equity

0.0

revenue

$0

operating Margin

0%

total Assets

$0

total Debt

$0

net Income

$0

eps

$0

gross Margin

0%

cash Position

$0

revenue Growth

+0%

Key Numbers

• 34 — Granted Patents (Number of patents owned or licensed by Radiopharm Theranostics Ltd, indicating its intellectual property strength.)
• 7 — Board Meetings (Number of Board of Directors meetings held during the fiscal year ended June 30, 2025, showing active governance.)
• 3 — Audit Committee Meetings (Number of Audit Committee meetings held during the fiscal year ended June 30, 2025, indicating oversight activity.)
• 3 — Remuneration Committee Meetings (Number of Remuneration Committee meetings held during the fiscal year ended June 30, 2025, showing executive compensation oversight.)
• 2036 — PD-L1-a China Patent Expiry (Earliest expiry date for a key PD-L1 patent in a major market.)
• 2039 — PD-L1-b US Patent Expiry (Latest expiry date for a key PD-L1 patent in a major market.)
• 2038 — HER-2 Patent Expiry (Expiry date for the HER-2 patent in China, Japan, and US.)
• 2041 — PTK7 Earliest Patent Expiry (Earliest expiry date for the PTK7 patent, indicating long-term protection for a newer asset.)
• 2037 — PSA-mAb US/Europe Patent Expiry (Expiry date for the PSA-mAb patent in key markets like US and Europe.)
• 2,364,949,502 — Ordinary Shares Outstanding (Total ordinary shares outstanding as of June 30, 2025, relevant for per-share metrics.)

Key Players & Entities

• Radiopharm Theranostics Ltd (company) — Registrant
• Riccardo Canevari (person) — Chief Executive Officer and Managing Director
• Paul Hopper (person) — Board Member
• Ian Turner (person) — Board Member, Audit Committee attendee
• Hester Larkin (person) — Board Member, Audit and Remuneration Committee attendee
• Leila Alland (person) — Board Member, Remuneration Committee attendee
• Phillip Hains (person) — Board Member
• Noel Donnelly (person) — Board Member, Audit and Remuneration Committee attendee
• Securities and Exchange Commission (regulator) — Filing recipient
• Sarbanes-Oxley Act of 2002 (regulator) — Compliance framework

FAQ

Risk Factors

• Patent Expiry and Exclusivity [medium — regulatory]: Radiopharm Theranostics holds 34 granted patents, with key assets like PD-L1, HER-2, and PSA-mAb having expiry dates ranging from 2036 to 2039. The loss of patent protection for these critical therapeutic targets could lead to increased competition from generic or biosimilar products, impacting market share and pricing power.
• Dependence on Licensed Technology [medium — operational]: The company's portfolio includes both owned and licensed intellectual property. Reliance on licensed patents introduces risks related to licensing agreement terms, potential disputes, or the inability to renew licenses, which could disrupt product development and commercialization.
• Clinical Trial Success and Regulatory Approval [high — regulatory]: The success of Radiopharm's pipeline assets, such as those targeting PD-L1, HER-2, and TROP-2, is contingent on successful clinical trials and subsequent regulatory approvals. Failure to demonstrate efficacy or safety in clinical studies, or delays in the approval process, would significantly impact the company's ability to generate revenue.

Industry Context

Radiopharm Theranostics operates in the highly competitive and innovation-driven biopharmaceutical sector, focusing on radiopharmaceuticals for cancer diagnosis and therapy. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Key trends include the advancement of targeted therapies, personalized medicine, and the integration of diagnostic imaging with therapeutic agents (theranostics).

Regulatory Implications

The company's reliance on patents for its core assets means that patent expiry dates are critical. Loss of exclusivity could expose Radiopharm to generic competition, necessitating a strong pipeline of new products or alternative revenue streams. Compliance with FDA and other global regulatory bodies for clinical trials and drug approval remains a paramount ongoing challenge.

What Investors Should Do

1. Monitor patent expiry dates and competitive landscape.
2. Evaluate progress in clinical trials and regulatory submissions.
3. Assess the company's strategy for pipeline diversification and lifecycle management.

Key Dates

• 2025-06-30: Fiscal Year End — Marks the end of the reporting period for the 20-F/A filing, providing updated financial and operational data.
• 2036-XX-XX: PD-L1-a China Patent Expiry — Indicates the earliest expiry of a key patent for a significant therapeutic target in a major market, signaling potential future competition.
• 2037-XX-XX: PD-L1-b US Patent Expiry — Represents a later expiry for a related PD-L1 patent in a key market, providing a longer period of exclusivity for this asset.
• 2038-XX-XX: HER-2 Patent Expiry — Marks the expiry of patent protection for the HER-2 asset in major markets, influencing future market dynamics.
• 2039-XX-XX: PD-L1-b Japan/Europe Patent Expiry — Indicates the expiry of PD-L1 patents in additional key international markets.
• 2041-XX-XX: PTK7 Earliest Patent Expiry — Shows long-term patent protection for the PTK7 asset, suggesting continued exclusivity for this pipeline candidate.

Glossary

Form 20-F/A

An amendment to a Form 20-F, which is an annual report filed by foreign private issuers with the U.S. Securities and Exchange Commission (SEC). The 'A' signifies an amendment to a previously filed document. (This filing provides updated information on Radiopharm Theranostics' intellectual property and board practices.)

Intellectual Property (IP)

Legal rights granted to creators and owners of original works, including patents, trademarks, copyrights, and trade secrets. (Crucial for pharmaceutical companies like Radiopharm, as patents protect their drug candidates and therapeutic technologies.)

Granted Patents

Patents that have been officially issued by a government patent office, providing exclusive rights to the patent holder for a specified period. (The 34 granted patents indicate the extent of Radiopharm's protected innovations.)

PD-L1

Programmed death-ligand 1, a protein that plays a role in immune suppression. Inhibiting the PD-L1 pathway is a common strategy in cancer immunotherapy. (A key target for Radiopharm's therapeutic assets, with multiple patents protecting related technologies.)

HER-2

Human Epidermal growth factor Receptor 2, a protein that can be overexpressed in certain types of cancer, such as breast and gastric cancers. (Another significant target for Radiopharm's drug development, protected by patents expiring in 2038.)

Sarbanes-Oxley Act (SOX)

A U.S. federal law that mandates certain practices in financial record keeping and reporting for public companies. (The CEO and CFO certifications under Sections 302 and 906 attest to the accuracy of the financial reporting.)

Ordinary Shares

The most common type of stock issued by a company, representing ownership and typically carrying voting rights. (The total number of ordinary shares outstanding (2,364,949,502) is essential for calculating per-share financial metrics.)

Year-Over-Year Comparison

This filing is an amendment (20-F/A) primarily updating the Intellectual Property and Board Practices sections, rather than a full annual report. Therefore, direct year-over-year comparisons of financial metrics like revenue, net income, or margins are not possible based on this specific amendment. The key updates focus on the company's patent portfolio, including specific expiry dates for critical assets like PD-L1 and HER-2, and details on board and committee meeting attendance, indicating active governance.

Filing Documents

• ea0268802-20fa1_radiopharm.htm (20-F/A) — 81KB
• ea026880201ex12-1_radio.htm (EX-12.1) — 9KB
• ea026880201ex12-2_radio.htm (EX-12.2) — 9KB
• ea026880201ex13-1_radio.htm (EX-13.1) — 3KB
• ea026880201ex13-2_radio.htm (EX-13.2) — 3KB
• 0001213900-25-119835.txt ( ) — 332KB
• radx-20250630.xsd (EX-101.SCH) — 3KB
• radx-20250630_def.xml (EX-101.DEF) — 17KB
• radx-20250630_lab.xml (EX-101.LAB) — 36KB
• radx-20250630_pre.xml (EX-101.PRE) — 19KB
• ea0268802-20fa1_radiopharm_htm.xml (XML) — 7KB

History and Development of the Company

Item 4. History and Development of the Company B. Business Overview Intellectual Property We have implemented a patent acquisition and licensing strategy as we develop our products and therapies in conjunction with our scientific advisory board. Currently, we own, or have licensed rights under, 34 granted patents. A summary of the number of patents and patent applications, patent types and jurisdictions is listed in the table below. Once converted to the complete stage as a PCT application, the provisional patent applications will also be applicable to all PCT contracting states. Various patents have been granted. For earlier stage applications where a PCT application has been filed but no related patents have yet reached the grant stage, international search reports and written opinions of the International Search Authority or the International Preliminary Examining Authority have considered that the Patent Cooperation Treaty applications contain at least some claims which are novel and inventive over the cited prior art and which meet the requirements of industrial applicability. The preparation of the International Search Report (ISR) and International Search Opinion (ISO) for PCT applications is one of the main procedural steps of the international phase of the Patent Cooperation Treaty (PCT). The purpose of conducting the searches at the international phase is to identify the relevant prior art and for the International Searching Authority to establish a preliminary, non-binding opinion as to whether the search and examined claims are novel, involve an inventive step and are industrially applicable. In addition to pursing patent protection for all of our assets, we rely on unpatented trade secrets, know-how and other confidential information as well as proprietary technological innovation and expertise that are protected in part by confidentiality and invention assignment agreements with our employees, advisors and consultants. Patent matters in biotech

: Directors, Senior Management and Employees

Item 6: Directors, Senior Management and Employees C. Board Practices The Board meets to discuss business regularly throughout the year, with additional meetings being held when circumstances warrant. Included in the table below are details of the meetings of the Board and the sub-committees of the Board that were held during the fiscal year ending June 30, 2025. Directors' meetings Audit Committee meetings Remuneration Committee meetings Attended Eligible Attended Eligible Attended Eligible Mr. Paul Hopper 7 7 - - - - Mr. Riccardo Canevari 7 7 - - - - Mr. Ian Turner 7 7 3 3 - - Ms. Hester Larkin 6 7 3 3 3 3 Dr. Leila Alland 7 7 - 1 3 3 Mr. Phillip Hains 7 7 - - - - Mr. Noel Donnelly 5 5 2 2 1 1

Exhibits

Item 19. Exhibits 12.1* Certification of the Chief Executive Officer pursuant to rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to section 302 of the Sarbanes-Oxley Act of 2002. 12.2* Certification of the Chief Financial Officer pursuant to rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to section 302 of the Sarbanes-Oxley Act of 2002. 13.1* Certification of the Chief Executive Officer pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002 13.2* Certification of the Chief Financial Officer pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002 * Filed herewith. 3

SIGNATURES

SIGNATURES The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F/A and that it has duly caused and authorized the undersigned to sign this annual report on its behalf. RADIOPHARM THERANOSTICS LIMITED Date: December 10, 2025 By: /s/ Riccardo Canevari Name: Riccardo Canevari Title: Chief Executive Officer and Managing Director 4

View Full Filing

View this 20-F/A filing on SEC EDGAR